Invero Pharma Secures Exclusive Xenon Clinical Supply Agreement
[MONTVILLE, NEW JERSEY, USA, January 17, 2023] A life-saving Orphan Drug for cardiac arrest patients which has been awarded FDA Fast-Track status is moving forward to phase 3 development after key agreement. (Read More)
Invero Pharma Secures Exclusive Xenon Data Rights
[MONTVILLE, NEW JERSEY, USA, March 9, 2022] – XENEX® is literally a last gasp product. It is being developed to treat patients resuscitated after having a heart attack but who remain comatose. This condition is so dire that the only currently approved treatment is to cool the patient’s body, hoping to preserve the brain. (Read More)
Invero Pharma acquires assets of Neuroprotexeon
[Montville, NEW JERSEY June 29, 2021] – Invero Pharma LLC announces it has acquired the assets and
intellectual property of Neuroprotexeon Inc. The assets include the rights to develop and
commercialize XENEX® (xenon gas and device for inhalation) as a potent neuro-protectant with an
exceptional safety profile. (Read More)